€11.20
4.63%
Madrid, Jan 02, 05:35 pm CET
Why the stock moved Why the stock moved Beta
ISIN
ES0171996087
Symbol
GRF

Grifols Stock price

€11.20
+0.77 7.33% 1M
+0.60 5.61% 6M
+0.50 4.63% YTD
+1.74 18.39% 1Y
-0.03 0.27% 3Y
-12.90 53.53% 5Y
-9.31 45.39% 10Y
+8.65 339.88% 20Y
Madrid, Closing price Fri, Jan 02 2026
+0.50 4.63%
ISIN
ES0171996087
Symbol
GRF
Industry

New AI Insights on Grifols Insights AI Insights on Grifols

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€6.5b
Enterprise Value
€15.4b
Net debt
€8.9b
Cash
€825.5m
Shares outstanding
679.7m
Valuation (TTM | estimate)
P/E
20.4 | 14.4
P/S
0.9 | 0.9
EV/Sales
2.1 | 2.0
EV/FCF
17.9
P/B
1.3
Dividends
DPS
€0.00
Yield 1Y | 5Y
0.0% | 0.6%
Growth 1Y | 5Y
- | -100.0%
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€7.5b | €7.6b
EBITDA
€2.1b | €1.8b
EBIT
€1.4b | €1.4b
Net Income
€372.7m | €529.8m
Free Cash Flow
€858.1m
Growth (TTM | estimate)
Revenue
7.3% | 5.4%
EBITDA
1.1% | 39.0%
EBIT
35.9% | 19.0%
Net Income
158.9% | 237.6%
Free Cash Flow
509.4%
Margin (TTM | estimate)
Gross
39.1%
EBITDA
28.2% | 24.1%
EBIT
18.1%
Net
5.0% | 7.0%
Free Cash Flow
11.4%
Financial Health
Equity Ratio
27.5%
Return on Equity
2.7%
ROCE
7.7%
ROIC
-
Debt/Equity
1.9
More
EPS
€0.6
FCF per Share
€1.3
Short interest
-
Employees
24k
Rev per Employee
€300.0k
Show more

Is Grifols a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Grifols Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Grifols forecast:

14x Buy
70%
4x Hold
20%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Grifols forecast:

Buy
70%
Hold
20%
Sell
10%

Financial data from Grifols

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
7,518 7,518
7% 7%
100%
- Direct Costs 4,580 4,580
7% 7%
61%
2,939 2,939
8% 8%
39%
- Selling and Administrative Expenses 1,125 1,125
12% 12%
15%
- Research and Development Expense 377 377
10% 10%
5%
2,117 2,117
1% 1%
28%
- Depreciation and Amortization 760 760
31% 31%
10%
EBIT (Operating Income) EBIT 1,358 1,358
36% 36%
18%
Net Profit 373 373
159% 159%
5%

In millions EUR.

Don't miss a Thing! We will send you all news about Grifols directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today